C07K 14/04
Varicella-zoster virus
C07K14/04 (Varicella-zoster virus) appears on 9 US grants and 17 published applications in this corpus.
Search patents in C07K- Granted patents
- 9
- Published applications
- 17
- Assignees
- 12
- Inventors
- 57
- Latest grant
- 15 Apr 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 2 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 1 | 1 |
| 2020 | 0 | 1 |
| 2021 | 1 | 4 |
| 2022 | 1 | 1 |
| 2023 | 0 | 0 |
| 2024 | 2 | 1 |
| 2025 | 2 | 3 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses15 Apr 2025US 12,276,665 B2Aicuris Anti-Infective Cures GmbH
- Activin receptor type IIB variants and methods of use thereof8 Apr 2025US 12,269,858 B2Keros Therapeutics, Inc.
- Expression cassette with a SynP160 promoter30 Jan 2024US 11,883,507 B2Friedrich Miescher Institute for Biomedical Research
- Activin receptor type IIB variants and methods of use thereof30 Jan 2024US 11,884,715 B2Keros Therapeutics, Inc.
- Re-directed immunotherapy1 Feb 2022US 11,236,131 B2The University of Birmingham
- Fusion protein of ge and gi of varicella-zoster virus and use6 Aug 2026US 2026/0224694 A1
- Nucleic Acid Vaccines for Varicella-Zoster Virus (VZV)6 Aug 2026US 2026/0224695 A1Everest Medicines (Singapore) Pte. Ltd.
- Modified varicella zoster virus glycoprotein e proteins23 Oct 2025US 2025/0325656 A1Glaxosmithkline Biologicals SA
- Truncated varicella-zoster virus envelope glycoprotein ge24 Jul 2025US 2025/0236646 A1Xiamen Innovax Biotech Co., Ltd.
- Activin receptor type iib variants and methods of use thereof26 Jun 2025US 2025/0206799 A1Keros Therapeutics, Inc.
Most cited
By later US patents
- Activin receptor type IIB variants and methods of use thereof6US 11,884,715 B2Keros Therapeutics, Inc. · 2024
- SynP160, a promoter for the specific expression of genes in rod photoreceptors4US 10,994,026 B2Friedrich Miescher Institute for Biomedical Research · 2021
- Re-directed immunotherapy4US 9,402,916 B2The University of Birmingham · 2016
- Re-directed immunotherapy3US 9,358,282 B2The University of Birmingham · 2016
- Re-directed immunotherapy2US 11,236,131 B2The University of Birmingham · 2022